Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free DFTX Stock Alerts

Definium Therapeutics (DFTX) Competitors

Definium Therapeutics logo
$42.32 +0.53 (+1.27%)
As of 04:00 PM Eastern
Compare

DFTX vs. BTSG, FMS, PACS, HIMS, and BLLN

Should you buy Definium Therapeutics stock or one of its competitors? MarketBeat compares Definium Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Definium Therapeutics include BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), PACS Group (PACS), Hims & Hers Health (HIMS), and Billiontoone (BLLN).

How does Definium Therapeutics compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.8% of BrightSpring Health Services shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BrightSpring Health Services currently has a consensus price target of $70.71, suggesting a potential upside of 12.78%. Definium Therapeutics has a consensus price target of $54.85, suggesting a potential upside of 29.60%. Given Definium Therapeutics' higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than BrightSpring Health Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
3.00
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
3.00

BrightSpring Health Services has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

BrightSpring Health Services has a net margin of 2.55% compared to Definium Therapeutics' net margin of 0.00%. BrightSpring Health Services' return on equity of 16.73% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BrightSpring Health Services2.55% 16.73% 5.24%
Definium Therapeutics N/A -100.30%-69.22%

BrightSpring Health Services has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$12.91B0.96$190.67M$1.6637.77
Definium TherapeuticsN/AN/A-$183.79M-$2.49N/A

In the previous week, BrightSpring Health Services had 17 more articles in the media than Definium Therapeutics. MarketBeat recorded 22 mentions for BrightSpring Health Services and 5 mentions for Definium Therapeutics. BrightSpring Health Services' average media sentiment score of 0.80 beat Definium Therapeutics' score of 0.38 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BrightSpring Health Services
7 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Definium Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

BrightSpring Health Services beats Definium Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fresenius Medical Care AG & Co. KGaA has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.88% compared to Definium Therapeutics' net margin of 0.00%. Fresenius Medical Care AG & Co. KGaA's return on equity of 8.90% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fresenius Medical Care AG & Co. KGaA4.88% 8.90% 4.05%
Definium Therapeutics N/A -100.30%-69.22%

In the previous week, Fresenius Medical Care AG & Co. KGaA had 8 more articles in the media than Definium Therapeutics. MarketBeat recorded 13 mentions for Fresenius Medical Care AG & Co. KGaA and 5 mentions for Definium Therapeutics. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.86 beat Definium Therapeutics' score of 0.38 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fresenius Medical Care AG & Co. KGaA
7 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Definium Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Fresenius Medical Care AG & Co. KGaA currently has a consensus price target of $23.95, indicating a potential downside of 0.42%. Definium Therapeutics has a consensus price target of $54.85, indicating a potential upside of 29.60%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fresenius Medical Care AG & Co. KGaA
5 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.55
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
3.00

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$22.20B0.58$1.11B$1.9012.66
Definium TherapeuticsN/AN/A-$183.79M-$2.49N/A

Summary

Fresenius Medical Care AG & Co. KGaA beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to PACS Group?

PACS Group (NYSE:PACS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

PACS Group has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

PACS Group currently has a consensus target price of $50.60, indicating a potential upside of 13.07%. Definium Therapeutics has a consensus target price of $54.85, indicating a potential upside of 29.60%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than PACS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PACS Group
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, PACS Group had 5 more articles in the media than Definium Therapeutics. MarketBeat recorded 10 mentions for PACS Group and 5 mentions for Definium Therapeutics. PACS Group's average media sentiment score of 1.20 beat Definium Therapeutics' score of 0.38 indicating that PACS Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PACS Group
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Definium Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

PACS Group has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PACS Group$5.29B1.34$191.54M$1.5628.69
Definium TherapeuticsN/AN/A-$183.79M-$2.49N/A

27.9% of Definium Therapeutics shares are held by institutional investors. 70.1% of PACS Group shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PACS Group has a net margin of 4.49% compared to Definium Therapeutics' net margin of 0.00%. PACS Group's return on equity of 26.47% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PACS Group4.49% 26.47% 4.36%
Definium Therapeutics N/A -100.30%-69.22%

Summary

PACS Group beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Hims & Hers Health has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

Definium Therapeutics has a net margin of 0.00% compared to Hims & Hers Health's net margin of -0.56%. Hims & Hers Health's return on equity of 6.10% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hims & Hers Health-0.56% 6.10% 1.52%
Definium Therapeutics N/A -100.30%-69.22%

In the previous week, Hims & Hers Health had 22 more articles in the media than Definium Therapeutics. MarketBeat recorded 27 mentions for Hims & Hers Health and 5 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.38 beat Hims & Hers Health's score of 0.24 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hims & Hers Health
4 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
5 Negative mention(s)
3 Very Negative mention(s)
Neutral
Definium Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Hims & Hers Health presently has a consensus price target of $31.43, indicating a potential downside of 2.02%. Definium Therapeutics has a consensus price target of $54.85, indicating a potential upside of 29.60%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hims & Hers Health
1 Sell rating(s)
11 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.19
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
3.00

Hims & Hers Health has higher revenue and earnings than Definium Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hims & Hers Health$2.35B3.16$128.37M-$0.09N/A
Definium TherapeuticsN/AN/A-$183.79M-$2.49N/A

Summary

Hims & Hers Health beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Billiontoone?

Definium Therapeutics (NASDAQ:DFTX) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Billiontoone's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -100.30% -69.22%
Billiontoone N/A N/A N/A

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 50.2% of Billiontoone shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Definium Therapeutics presently has a consensus target price of $54.85, indicating a potential upside of 29.60%. Billiontoone has a consensus target price of $126.00, indicating a potential downside of 11.59%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Definium Therapeutics is more favorable than Billiontoone.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
3.00
Billiontoone
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Billiontoone had 3 more articles in the media than Definium Therapeutics. MarketBeat recorded 8 mentions for Billiontoone and 5 mentions for Definium Therapeutics. Billiontoone's average media sentiment score of 0.69 beat Definium Therapeutics' score of 0.38 indicating that Billiontoone is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Billiontoone
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Billiontoone has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$2.49N/A
Billiontoone$305.11M21.48$7.45M$0.55259.13

Summary

Billiontoone beats Definium Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DFTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DFTX vs. The Competition

Export
MetricDefinium TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.22B$11.46B$6.80B$13.02B
Dividend YieldN/A2.74%2.60%10.03%
P/E Ratio-17.00791.61279.7225.54
Price / SalesN/A947.20648.69115.96
Price / CashN/A14.8228.6434.82
Price / Book12.6010.4411.126.36
Net Income-$183.79M$2.81B$3.48B$347.58M
7 Day Performance0.86%1.84%2.58%3.16%
1 Month Performance-4.23%-3.13%-2.79%-2.06%
1 Year Performance352.14%154.82%64.28%21.19%

Definium Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DFTX
Definium Therapeutics
3.5183 of 5 stars		$42.32
+1.3%		$54.85
+29.6%		+395.1%$4.22BN/AN/A40
BTSG
BrightSpring Health Services
4.8523 of 5 stars		$71.98
-1.3%		$70.12
-2.6%		+207.9%$14.38B$12.91B51.0523,500
FMS
Fresenius Medical Care AG & Co. KGaA
3.9128 of 5 stars		$24.90
+1.3%		$28.00
+12.4%		+1.0%$13.21B$22.20B13.111,488
PACS
PACS Group
3.7659 of 5 stars		$46.95
+0.2%		$50.60
+7.8%		+320.1%$7.42B$5.29B30.0947,455
HIMS
Hims & Hers Health
2.2534 of 5 stars		$30.23
+7.6%		$31.43
+4.0%		-50.7%$6.50B$2.35BN/A2,442

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DFTX) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners
This metric called 1929, 1969 and 2000 [it's screaming now]
The Buffett Indicator once flagged the 1929, 1969, and 2000 market peaks - and it's now at 231%, its highest r...
Golden Portfolio | Sponsoredtc pixel
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel